Quick Answer
Stoke Therapeutics, Inc. reported R&D Expense of $137.92 million for fiscal year 2025.
Stoke Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $137.92M | +54.7% |
| 2024 | $89.13M | +8.4% |
| 2023 | $82.23M | +5.6% |
| 2022 | $77.84M | +43.7% |
| 2021 | $54.17M | +68.2% |
| 2020 | $32.20M | +35.5% |
| 2019 | $23.76M | +183.9% |
| 2018 | $8.37M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $37.70M | +69.8% | +45.8% |
| June 30, 2025 | $25.86M | +22.3% | -20.9% |
| March 31, 2025 | $32.68M | +46.1% | +47.2% |
| September 30, 2024 | $22.20M | +9.5% | +5.1% |
| June 30, 2024 | $21.14M | +2.8% | -5.5% |
| March 31, 2024 | $22.37M | +13.9% | +10.3% |
| September 30, 2023 | $20.27M | +0.8% | -1.4% |
| June 30, 2023 | $20.55M | +11.9% | +4.7% |
- Stoke Therapeutics, Inc. showed an increase of +54.7% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Stoke Therapeutics, Inc.’s r&d expense has grown by 1547.6% (from $8.37 million to $137.92 million).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: